Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,44 USD | -0,69% | -11,59% | -58,33% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 2,95 mln. 3,24 mln. 3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,11% |
Recentste transcriptie over Altamira Therapeutics
1 week | -11,59% | ||
Lopende maand | -7,64% | ||
1 maand | -27,50% | ||
3 maanden | -24,08% | ||
6 maanden | -31,92% | ||
Lopend jaar | -58,33% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 01-11-21 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 01-03-18 |
Mats Blom
BRD | Director/Board Member | 59 | 01-04-17 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
13-05-24 | 1,44 | -0,69% | 50 239 |
10-05-24 | 1,45 | -3,33% | 32 379 |
09-05-24 | 1,5 | +2,04% | 42 754 |
08-05-24 | 1,47 | -6,96% | 80 824 |
07-05-24 | 1,58 | -4,24% | 54 002 |
uitgestelde koers Nasdaq, 13 mei 2024 om 22:30 uur
Meer koersenKwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,66% | 109 mld. | |
+11,23% | 105 mld. | |
-0,38% | 22,25 mld. | |
-12,15% | 22,09 mld. | |
-7,66% | 18,68 mld. | |
-36,52% | 17,58 mld. | |
-10,09% | 16,85 mld. | |
+3,33% | 13,76 mld. | |
+36,58% | 12,46 mld. |
- Beurs
- Aandelen
- Koers CYTO
- Koers CYTO